BACKGROUND: Prostate cancer (PCa) remains the most common malignancy and the second leading cause of cancer death among men in the United States. PCa exhibits the most striking racial disparity, as African American men are at 1.4 times higher risk of being diagnosed, and 2-3 times higher risk of dying of PCa, compared to Caucasian men. The etiology of the disparity has not been clearly elucidated. The objective of this article is to critically review the literature and summarize the most prominent PCa racial disparities accompanied by proposed explanations. METHODS: The present literature on disparities at presentation, diagnosis, treatment, and survival of African American men affected by PCa was systematically reviewed. Original research as well as relevant review articles were included. RESULTS: African American men persistently present with more advanced disease than Caucasian men, are administered different treatment regimens than Caucasian men, and have shorter progression-free survival following treatment. In addition, African American men report more treatment-related side-effects that translates to the diminished quality of life (QOL). CONCLUSIONS: PCa racial disparity exists at stages of presentation, diagnosis, treatment regimens, and subsequent survival, and the QOL. The disparities are complex involving biological, socio-economic, and socio-cultural determinants. These mounting results highlight an urgent need for future clinical, scientific, and socio-cultural research involving transdisciplinary teams to elucidate the causes for PCa racial disparities.
BACKGROUND:Prostate cancer (PCa) remains the most common malignancy and the second leading cause of cancer death among men in the United States. PCa exhibits the most striking racial disparity, as African American men are at 1.4 times higher risk of being diagnosed, and 2-3 times higher risk of dying of PCa, compared to Caucasian men. The etiology of the disparity has not been clearly elucidated. The objective of this article is to critically review the literature and summarize the most prominent PCa racial disparities accompanied by proposed explanations. METHODS: The present literature on disparities at presentation, diagnosis, treatment, and survival of African American men affected by PCa was systematically reviewed. Original research as well as relevant review articles were included. RESULTS: African American men persistently present with more advanced disease than Caucasian men, are administered different treatment regimens than Caucasian men, and have shorter progression-free survival following treatment. In addition, African American men report more treatment-related side-effects that translates to the diminished quality of life (QOL). CONCLUSIONS:PCa racial disparity exists at stages of presentation, diagnosis, treatment regimens, and subsequent survival, and the QOL. The disparities are complex involving biological, socio-economic, and socio-cultural determinants. These mounting results highlight an urgent need for future clinical, scientific, and socio-cultural research involving transdisciplinary teams to elucidate the causes for PCa racial disparities.
Authors: Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey Journal: J Gen Intern Med Date: 2004-02 Impact factor: 5.128
Authors: Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich Journal: Proc Natl Acad Sci U S A Date: 2006-08-31 Impact factor: 11.205
Authors: Kathryn E Richert-Boe; Sheila Weinmann; Jean A Shapiro; Benjamin A Rybicki; Shelley M Enger; Stephen K Van Den Eeden; Noel S Weiss Journal: Urology Date: 2008-02-15 Impact factor: 2.649
Authors: Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Ethan M Lange; Aruna V Sarma; Anna Ray; Yunfei Wang; Lindsey A Ho; Sarah A Anderson; Julie M Cunningham; Kathleen A Cooney Journal: J Hum Genet Date: 2008-01-24 Impact factor: 3.172
Authors: Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard B Hayes Journal: Int J Cancer Date: 2007-11-15 Impact factor: 7.396
Authors: Elima Jedy-Agba; Maria Paula Curado; Olufemi Ogunbiyi; Emmanuel Oga; Toyin Fabowale; Festus Igbinoba; Gloria Osubor; Theresa Otu; Henry Kumai; Alice Koechlin; Patience Osinubi; Patrick Dakum; William Blattner; Clement A Adebamowo Journal: Cancer Epidemiol Date: 2012-05-22 Impact factor: 2.984
Authors: Robert Steven Gerhard; Dattatraya Patil; Yuan Liu; Kenneth Ogan; Mehrdad Alemozaffar; Ashesh B Jani; Omer N Kucuk; Viraj A Master; Theresa W Gillespie; Christopher P Filson Journal: Urol Oncol Date: 2017-01-12 Impact factor: 3.498
Authors: Susan Halabi; Sandipan Dutta; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Ian M Thompson; Kim N Chi; John C Araujo; Christopher Logothetis; David I Quinn; Karim Fizazi; Michael J Morris; Mario A Eisenberger; Daniel J George; Johann S De Bono; Celestia S Higano; Ian F Tannock; Eric J Small; William Kevin Kelly Journal: J Clin Oncol Date: 2018-12-21 Impact factor: 44.544
Authors: Craig Evan Pollack; Katrina A Armstrong; Nandita Mitra; Xinwei Chen; Katelyn R Ward; Archana Radhakrishnan; Michelle S Wong; Justin E Bekelman; Charles C Branas; Karin V Rhodes; David T Grande Journal: Cancer Date: 2017-07-20 Impact factor: 6.860
Authors: J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt Journal: Prostate Cancer Prostatic Dis Date: 2013-03-05 Impact factor: 5.554